RAS通路突变作为儿童B细胞前体急性淋巴细胞白血病治疗适配的预测生物标志物
该研究对461例初诊儿童B细胞前体急性淋巴细胞白血病(BCP-ALL)及19对诊断-复发配对样本进行13个RAS通路基因的靶向深度测序,发现44.2%患者存在突变,其中24.1%为克隆性突变;克隆性而非亚克隆性突变与标危和高危治疗患者的不良结局相关;RAS突变细胞对泼尼松龙和长春新碱耐药,对MEK抑制剂曲美替尼敏感,曲美替尼可使耐药细胞对泼尼松龙敏感。
要点
- 461例初诊儿童BCP-ALL中44.2%存在RAS通路突变,24.1%为克隆性突变。
- 克隆性而非亚克隆性RAS通路突变与标危和高危治疗患者的不良结局相关。
- RAS突变细胞对泼尼松龙和长春新碱耐药,对曲美替尼敏感,曲美替尼可使耐药细胞对泼尼松龙敏感。
核心结论
- RAS通路突变在初诊儿童BCP-ALL中常见,克隆性而非亚克隆性突变与不良风险参数相关。
- 这些突变可能筛选出适合MEK抑制剂治疗的患者。
研究设计与样本
- 对461例初诊儿童BCP-ALL病例及19对诊断-复发配对样本进行13个RAS通路基因的靶向深度测序。
主要发现
- 44.2%的患者存在RAS通路突变,其中24.1%携带克隆性突变。
- 突变频率在高超二倍体、婴儿t(4;11)重排、BCR-ABL1样和B-其他病例中最高(50-70%),在ETV6-RUNX1重排病例中较低,在TCF3-PBX1和BCR-ABL1重排病例中罕见(27-4%)。
- RAS通路突变细胞在体外对泼尼松龙和长春新碱更耐药。
- 克隆性而非亚克隆性突变与标危和高危治疗患者的不良结局相关。
- 复发时大多数RAS通路突变为克隆性(10个中有9个)。
临床怎么用
- 作者认为这些突变可能筛选出适合MEK抑制剂治疗的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RAS pathway mutations have been linked to relapse and chemotherapy resistance in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, comprehensive data on the frequency and prognostic value of subclonal mutations in well-defined subgroups using highly sensitive and quantitative methods are lacking. Targeted deep sequencing of 13 RAS pathway genes was performed in 461 pediatric BCP-ALL cases at initial diagnosis and in 19 diagnosis-relapse pairs. Mutations were present in 44.2% of patients, with 24.1% carrying a clonal mutation. Mutation frequencies were highest in high hyperdiploid, infant t(4;11)-rearranged, BCR-ABL1-like and B-other cases (50-70%), whereas mutations were less frequent in ETV6-RUNX1-rearranged, and rare in TCF3-PBX1- and BCR-ABL1-rearranged cases (27-4%). RAS pathway-mutated cells were more resistant to prednisolone and vincristine ex vivo. Clonal, but not subclonal, mutations were linked to unfavorable outcome in standard- and high-risk-treated patients. At relapse, most RAS pathway mutations were clonal (9 of 10). RAS mutant cells were sensitive to the MEK inhibitor trametinib ex vivo, and trametinib sensitized resistant cells to prednisolone. We conclude that RAS pathway mutations are frequent, and that clonal, but not subclonal, mutations are associated with unfavorable risk parameters in newly diagnosed pediatric BCP-ALL. These mutations may designate patients eligible for MEK inhibitor treatment.
引用
- Jerchel IS, Hoogkamer AQ, Ariës IM, et al. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia. Leukemia. 2017. PMID: 28972594. doi:10.1038/leu.2017.303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。